Clinical trial reportJournal of clinical oncology : official journal of the American Society of Clinical OncologyPublished
Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
Regional connection
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
- Institution
- Johnson & Johnson
- County
- Montgomery County
Publication record
- Type
- Clinical trial report
- Venue
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Published
- Topic
- Clinical care
- Subject terms
- T-Lymphocytes; Humans; Kallikreins; Tissue Kallikreins; Antibodies, Bispecific; Aged; Aged, 80 and over; Middle Aged; Male; Prostatic Neoplasms, Castration-Resistant
- PubMed ID
- 40450573
- PubMed Central ID
- PMC12288886
- Open access
- Yes, open
- Added to directory
- Source checked